• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喉癌的放射治疗——剂量与功能保留

[Radiotherapy of carcinoma of the larynx--dose and function preservation].

作者信息

Nakano M, Iida K, Sato S, Sakata S, Sueyama H

出版信息

Gan No Rinsho. 1985 Sep;31(12):1602-4.

PMID:4079049
Abstract

Relationship between irradiated dose and function preservation of the larynx in patients of laryngeal carcinoma (T1-T3) treated with radiotherapy were analysed and discussed. Local control rate for T1 and T2 lesion was highest in the dose range of 65-70 Gy. But in T3 lesion, especially of supraglottic cancer, the dose range to obtain highest local tumor control rate is above 76 Gy and higher than in case of T1 and T2 lesions. Laryngeal edema was seen in patients who were delivered the dose of 80 Gy. But total laryngectomy could be avoided by conservative therapy. Necessity of induction chemotherapy for advanced cases was also discussed.

摘要

分析并讨论了喉癌(T1-T3)患者接受放射治疗时照射剂量与喉功能保留之间的关系。T1和T2病变的局部控制率在65-70 Gy剂量范围内最高。但在T3病变中,尤其是声门上癌,获得最高局部肿瘤控制率的剂量范围高于76 Gy,且高于T1和T2病变。接受80 Gy剂量的患者出现了喉水肿。但通过保守治疗可避免全喉切除术。还讨论了晚期病例诱导化疗的必要性。

相似文献

1
[Radiotherapy of carcinoma of the larynx--dose and function preservation].喉癌的放射治疗——剂量与功能保留
Gan No Rinsho. 1985 Sep;31(12):1602-4.
2
Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.诱导化疗在喉保留策略中仍有作用吗?加泰罗尼亚肿瘤研究所对III期喉癌的治疗经验。
Laryngoscope. 2006 Sep;116(9):1651-6. doi: 10.1097/01.mlg.0000231736.08477.47.
3
Results of treatment of inoperable recurrences of laryngeal cancer after total laryngectomy.全喉切除术后不可手术切除的喉癌复发的治疗结果。
Strahlenther Onkol. 1996 Feb;172(2):99-102.
4
Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.晚期喉癌器官保留试验的语音和吞咽结果
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1395-9. doi: 10.1016/j.ijrobp.2005.05.004. Epub 2005 Aug 8.
5
[Induction chemotherapy and larynx preservation: is such practice useful?].[诱导化疗与喉保留:这种做法有用吗?]
Bull Cancer. 2002 Apr;89(4):411-7.
6
Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.T3-T4期咽喉部鳞状细胞癌的保守手术:对于诱导化疗敏感患者,是放疗和全喉切除术之外的另一种选择。
Laryngoscope. 2000 Mar;110(3 Pt 1):412-6. doi: 10.1097/00005537-200003000-00015.
7
[Preservation of the larynx in advanced cancer--experiences at the Oncology Department, Rambam Medical Center, Haifa].
Harefuah. 2000 Oct;139(7-8):271-4, 326.
8
Irradiated volume and arytenoid edema after radiotherapy for T1 glottic carcinoma.T1期声门癌放疗后的照射体积与杓状软骨水肿
Strahlenther Onkol. 1992 Jan;168(1):23-6.
9
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.同步化疗与调强放疗用于局部晚期喉癌和下咽癌的治疗
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68. doi: 10.1016/j.ijrobp.2007.03.013. Epub 2007 May 9.
10
Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.下咽和喉鳞状细胞癌T4期患者的同步放化疗
Auris Nasus Larynx. 2007 Dec;34(4):499-504. doi: 10.1016/j.anl.2007.02.004. Epub 2007 Jun 28.